32. Prioritize the pediatric TB diagnostic space to ensure there are improved tools for pediatric TB infection and disease detection to reach and maintain targets.

33. Develop quality-assured, affordable, less invasive alternative specimen processing methods or products (not based only on sputum) that can be used for the pediatric population, such as urine, stool or saliva.

34. Ensure diagnostic studies include children and alternative (non-sputum-based) sample types.

35. Expedite development of point-of-care biomarker-based tests for infants and children.

36. Consider moving from separate instrument, consumable, and service procurement towards more consolidated, all-inclusive pricing models, for both laboratory-based and point-of-care technologies.

37. Provide service level agreements that clearly spell out key performance indicators for all technology types and their offered service plans, plus a mitigation plan when the threshold is exceeded.

60. Prioritize attainment of WHO recommendation of the FluoroType MTBDR assay.

61. Prioritize obtaining waivers for GenoType and FluoroType assay technologies for countries under US embargo.

62. Offer access pricing and prospective reductions based on global volume thresholds; publish the volumes procured quarterly.

63. Consider introduction of a diagnostic connectivity solution that is API-capable for automatic reporting of line probe assay test results to users and other information management systems.